Seria a Doença de Parkinson Fator Protetor da Enxaqueca?

  • Celmir de Oliveira Vilaça Neurologista, Prefeitura Municipal de Duque de Caxias, Caxias-RJ, Brasil. Mestrando do Programa de pós-graduação em Neurologia/Neurociências da Universidade Federal Fluminense, Niterói-RJ, Brasil.
  • Marco Antonio Araujo Leite Neurologista, Doutor em Neurologia, Professor Adjunto de Neurologia da Universidade Federal Fluminense (UFF). MMC/Divisão de Neurologia. Setor de Desordens do Movimento da UFF, HUAP. Programa de pós-graduação em Neurologia/Neurociências, UFF, Niterói-RJ, Brasil.
  • Jano Alves de Souza Neurologista, Doutor em Neurologia, Professor Adjunto de Neurologia da Universidade Federal Fluminense (UFF). MMC/Divisão de Neurologia. Setor de Transtornos Cognitivos da Universidade Federal Fluminense da UFF, HUAP. Programa de pós-graduação em Neurologia/Neurociências, UFF. Niterói- RJ, Brasil.
  • João Santos Pereira Neurologista, Doutor em Neurologia, Professor Associado de Neurologia da Universidade do Estado do Rio de Janeiro. Setor de Desordens do Movimento da UERJ, HUPE, Rio de Janeiro-RJ, Brasil. Programa de pós-graduação em Neurologia/Neurociências, UFF. Niterói-RJ, Brasil.
  • Marco Orsini Médico, Doutor em Neurologia. Professor do Programa de pós-graduação em Neurologia/Neurociências, UFF. Niterói-RJ, Brasil. Programa de Mestrado em Ciências da Reabilitação - Centro Universitário Augusto Motta - UNISUAM, Rio de Janeiro-RJ, Brasil.
Palavras-chave: Cefaleia, Transtornos de Enxaqueca, Doença de Parkinson, Dopamina, Receptores Dopaminérgicos

Resumo

Objetivo. Realizar uma revisão sobre a participação das vias dopami­nérgicas na enxaqueca e discutir a hipótese que a Doença de Parkinson (DP), ao provocar a degeneração das vias dopaminérgicas, poderia ser­vir como fator protetor para enxaqueca. Método. Revisão não siste­mática de artigos utilizando-se os unitermos: “dopamine”, “migraine” e “Parkinson Disease”. Priorizou-se artigos que contivessem a associa­ção desses unitermos no título. Utilizou-se para a pesquisa as base de dados PubMed e Lilacs. Resultados. Foram escolhidos 32 artigos ori­ginais, 6 artigos de revisão e um manual. Conclusão. A enxaqueca se caracteriza por um estado de aumento da atividade dopaminérgica no sistema nervoso central (SNC), havendo evidências que a Doença de Parkinson poderia, ao provocar degeneração destas vias, dentre outras alterações no sistema nervoso central, servir como fator de proteção para enxaqueca.

Métricas

Carregando métricas...

Referências

Queiroz LP, Peres MFP, Piovesan EJ, Kowacs F, Ciciarelli MC, Souza JA, et al. A nationwide population-based study of migraine in Brazil. Cephalalgia 2009;29:642-9. http://dx.doi.org/10.1111/j.1468-2982.2008.01782.x

Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 2nd edn. Cephalalgia 2004;24:1-160.

Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4. http://dx.doi.org/10.1136/jnnp.55.3.181

Del Tredici K, Rüb U, De Vos RA, Bohl JR, Braak H. Where Does Parkinson Disease Pathology Begin in the Brain? J Neuropathol Exp Neurol 2002;61:413-26.

Peroutka SJ. Dopamine and migraine. Neurology 1997;49:650-6. http://dx.doi.org/10.1212/WNL.49.3.650

Akerman S, Goadsby PJ. Dopamine and migraine: biology and clinical implications. Cephalalgia 2007;27:130814. http://dx.doi.org/10.1111/j.1468-2982.2007.01478.x

Barbanti P, Fabbrini G, Vanacore N, Rum A, Lenzi G, Meco G, et al. Dopamine and migraine: does Parkinson’s disease modify migraine course? Cephalalgia 2000;20:720-3.

Van Hilten JJ. The migraine-dopamine link: do migraine and Parkinson’s disease coexist? Clin Neurol Neurosurg 1992;94:S168-70.

Murray CJL, Lopez AD. The Global Burden of Disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge, Harvard University Press on behalf of the World Health Organization and the World Bank, 1996; p.11.

Osterhaus JT, Townsend RJ, Gandek B,Ware JE. Measuring the Functional Status and Well-Being of Patients with Migraine Headache. Headache 1994; 34:337-43. http://dx.doi.org/10.1111/j.1526-4610.1994.hed3406337.x

Evans RW. Mannix L K Expert Opinion. Triptans for Migraine Prodrome. Headache 2002;42:83-4. http://dx.doi.org/10.1046/j.1526-4610.2002.02018.x

Welch KMA. Contemporary concepts of migraine pathogenesis. Neurology 2003;61:S2-8.

Izzati-Zade K F. The Role of Serotonin in the Pathogenesis and Clinical Presentations of Migraine Attacks. Neurosci Behav Physiol 2008;38:501-5. http://dx.doi.org/10.1007/s11055-008-9008-3

Panconesi A.Serotonin and migraine: a reconsideration of the central theory. J Headache Pain 2008;9:267-76. http://dx.doi.org/10.1007/s10194-008-0058-2

Gladstone JP. Dopamine and migraine: trigeminovascular nociception genetics and therapeutics. Cephalalgia 2007; 27:1315-20. http://dx.doi.org/10.1111/j.1468-2982.2007.01479.x

Charbit AR, Akerman S, Goadsby PJ. Dopamine: what’s new in migraine? Curr Opin Neurol 2010; 23:275-81.

Rhode AM, Hösing VG, Happe S, Biehl K, Young P, Evers S. Comorbidity of migraine and restless legs syndrome a case-control study. Cephalalgia, 2007;27:1255-60. http://dx.doi.org/10.1111/j.1468-2982.2007.01453.x

Charbit AR, Akerman S, Holland PR, Goadsby PJ. Neurons of the dopaminergic/calcitonin gene-related peptide A11 cell group modulate neuronal firing in the trigeminocervical complex: an electrophysiological and immunohistochemical study. J Neurosci. 2009 Oct 7;29:12532-41.

Palmas MA, Cherchi A, Stochino E, Congiu D, Del Zompo M. Dopamine genes and migraine. J Headache and Pain 2000;1:S153-6.

Cave J, Baker H. Dopamine Systems in the Forebrain. Adv Exp Med Biol 2009;651:15-35. http://dx.doi.org/10.1007/978-1-4419-0322-8_2

Peroutka SJ, Wilhoit T, Jones K. Clinical susceptibility to migraine with aura is modified by dopamine D, receptor (DRD2) NcoI alleles. Neurology 1997;49:201-6. http://dx.doi.org/10.1212/WNL.49.1.201

Del Zompo M, Cherchi A, Palmas MA, Ponti M, Bocchetta A, Gessa GL, et al. Association between dopamine receptor genes and migraine without aura in a Sardinian sample. Neurology 1998;58:781-6. http://dx.doi.org/10.1212/WNL.51.3.781

Lea RA, Dohy A, Jordan K, Quinlan S, Brimage PJ, Griffiths LR. Evidence for allelic association of the dopamine b-hydroxylase gene (DBH) with susceptibility to typical migraine. Neurogenetics 2000;3:35-40.

Fernandez F, Colson N, Quinlan S, MacMillan J, Lea RA, Griffiths LR. Association between migraine and a functional polymorphism at the dopamine β-hydroxylase locus. Neurogenetics 2009;10:199-208. http://dx.doi.org/10.1007/s10048-009-0176-2

McCallum LK, Fernandez F, Quinlan S, Macartney DP, Lea RA, Griffiths LR. Association study of a functional variant in intron 8 of the dopamine transporter gene and migraine susceptibility. Eur J Neurol 2007; 14:706-7. http://dx.doi.org/10.1111/j.1468-1331.2007.01800.x

Karwautz A, Campos de Sousa S, Konrad A, Zesch HE, Wagner G, Zormann A,et al. Family-based association analysis of functional VNTR polymorphisms in the dopamine transporter gene in migraine with and without aura. J Neural Transm 2008;115:91-5. http://dx.doi.org/10.1007/s00702-007-0799-0

Haan J, Hollander J, Ferrari MD. Migraine in the elderly: a review. Cephalalgia 2006;27:97-106. http://dx.doi.org/10.1111/j.1468-2982.2006.01250.x

Martin VT, Behbehani M. Ovarian Hormones and Migraine Headache: Understanding Mechanisms and Pathogenesis - Part I. Headache 2006;46:3-23. http://dx.doi.org/10.1111/j.1526-4610.2006.00309.x

Watson CS, Alyea RA, Hawkins BE, Thomas ML, Cunningham KA, Jakubas AA. Estradiol effects on the dopamine transporter – protein levels, subcellular location, and function. J Mol Signal 2006;1:5. http://dx.doi.org/10.1186/1750-2187-1-5

Krimer LS, Muly EC 3rd, Williams GV, Goldman-Rakic PS. Dopaminergic regulation of cerebral cortical microcirculation. Nature Neuroscience 1998;1:286-9. http://dx.doi.org/10.1038/1099

Cubo E, Kompoliti K, Leurgans SE, Raman R. Dopaminergic Hypersensitivity In Patients With Parkinson Disease And Migraine. Clin Neuropharmacol 2004;27:30-2. http://dx.doi.org/10.1097/00002826-200401000-00009

McGeeney BE. Dopamine Antagonists and Migraine. Drug Dev Res 2007;68:341-5. http://dx.doi.org/10.1002/ddr.20198

Cupini LM, Troisi E, Placidi F, Diomedi M, Silvestrini M, Argiro G, et al. Does the antimigraine action of flunarizine involve the dopaminergic system? A clinical-neuroendocrinological study. Cephalalgia 1999;19:27-31. http://dx.doi.org/10.1111/j.1468-2982.1999.1901027.x

Honkaniemi J, Liimatainen S, Rainesalo S, Sulavuori S. Haloperidol in the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study. Headache 2006;46:781-7. http://dx.doi.org/10.1111/j.15264610.2006.00438.x

Bigal ME, Bordini CA, Speciali JG. Intravenous chlorpromazine in the emergency department treatment of migraines: A Randomized Controlled Trial. JEM 2002;23:141-8.

Da Costa AR, Monzillo PH, Sanvito WL. Uso da clorpromazina para tratamento de cefaléia no serviço de emergência. Arq Neuropsiquiatr 1988;66(3B):565-8.

Lang AE. Acute Orthostatic Hypotension When Starting Dopamine Agonist Therapy in Parkinson Disease: The Role of Domperidone Therapy. Letters to the Editor. Arch Neurol 2001;58:835.

Piovesan EJ, Lange MC, Teive HAG, Tatsui CE, Kowacs PA, Piovesan LM, et al. Mudança no padrão biológico da migrânea com aura após utilização da tetrabenazina. Arq Neuropsiquiatr 2000;58(2B):566-71.

Mascia A, Afra J, Schoenen J. Dopamine and migraine: a review of pharmacological, biokhemical, neurophysiological, and-therapeutic-data. Cephalalgia 1998;18:174-82. http://dx.doi.org/10.1046/j.14682982.1998.1804174.x

Publicado
2013-09-30
Como Citar
Vilaça, C. de O., Leite, M. A. A., Souza, J. A. de, Pereira, J. S., & Orsini, M. (2013). Seria a Doença de Parkinson Fator Protetor da Enxaqueca?. Revista Neurociências, 21(3), 455-460. https://doi.org/10.34024/rnc.2013.v21.8262
Seção
Artigos de Revisão